I quite liked this part of the article 'but an increase in generic-drug approvals brought year-over-year sales growth of 4.5%, according to data cited by Wilbur'. It lines up well with this from MYX 'Targeting 8 new product launches by the end of CY20 of which 2 are already approved and 3have no generic equivalents today', and this 'The Company has three women’s health contraceptive generic products in its pipeline targetingmarkets with IQVIA sales of US$1.1b including a generic NUVARING®, which is the largestcontraceptive sold in the US$5.5b US contraceptive market with no generic equivalents today'.
Whether you like or hate MYX management, one cannot dispute the fact they keep rolling onward.
MYX Price at posting:
44.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)